Combination of Hypofractionated Radiotherapy and Glofitamab for Relapsed or Refractory DLBCL With High Tumor Burden: A Case Series

Jingshu Meng; Qiuhui Li; Fang Zhu; Lu Zhou; Xinxiu Liu; Tao Liu; Chunxia Qin; Huaxiong Pan; Baixin Ye; Liling Zhang

doi:10.1002/mog2.70077

MEDCOMM - Oncology ›› 2026, Vol. 5 ›› Issue (2) :e70077 DOI: 10.1002/mog2.70077

LETTER

Combination of Hypofractionated Radiotherapy and Glofitamab for Relapsed or Refractory DLBCL With High Tumor Burden: A Case Series

Jingshu Meng ¹^,²^,³
, Qiuhui Li ¹^,²^,³
, Fang Zhu ¹^,²^,³
, Lu Zhou ¹^,²^,³
, Xinxiu Liu ¹^,²^,³
, Tao Liu ¹^,²^,³
, Chunxia Qin ⁴
, Huaxiong Pan ⁵
, Baixin Ye ⁶
, Liling Zhang ¹^,²^,³

Author information +

History +

PDF (953KB)

Cite this article

Download citation ▾

Jingshu Meng, Qiuhui Li, Fang Zhu, Lu Zhou, Xinxiu Liu, Tao Liu, Chunxia Qin, Huaxiong Pan, Baixin Ye, Liling Zhang. Combination of Hypofractionated Radiotherapy and Glofitamab for Relapsed or Refractory DLBCL With High Tumor Burden: A Case Series. MEDCOMM - Oncology, 2026, 5 (2) : e70077 DOI:10.1002/mog2.70077

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	A. M. Bock and N. Epperla, “Therapeutic Landscape of Primary Refractory and Relapsed Diffuse Large B-Cell Lymphoma: Recent Advances and Emerging Therapies,” Journal of Hematology & Oncology 18, no. 1 (2025): 68.

[2]	M. J. Dickinson, C. Carlo-Stella, F. Morschhauser, et al., “Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma,” New England Journal of Medicine 387, no. 24 (2022): 2220–2231.

[3]	H. Li, N. A. Mayr, R. J. Griffin, et al., “Overview and Recommendations for Prospective Multi-Institutional Spatially Fractionated Radiation Therapy Clinical Trials,” International Journal of Radiation OncologyBiologyPhysics 119, no. 3 (2024): 737–749.

[4]	R. Schmitz, G. W. Wright, D. W. Huang, et al., “Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma,” New England Journal of Medicine 378, no. 15 (2018): 1396–1407.

[5]	P. Vodárek, D. Écsiová, V. Řezáčová, et al., “A Comprehensive Assessment of Lymphocyte Subsets, Their Prognostic Significance, and Changes After First-Line Therapy Administration in Patients With Chronic Lymphocytic Leukemia,” Cancer Medicine 12, no. 6 (2023): 6956–6970.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm - Oncology published by John Wiley & Sons Australia, Ltd on behalf of Sichuan International Medical Exchange & Promotion Association (SCIMEA).